Curia said the changes reflect the accelerated organizational integration of the subsidiaries into the new owner’s provision of comprehensive biologics discovery, development and manufacturing solutions to customers. The acquisition of Integrity Bio closed in August 2021 and the LakePharma transaction in September of that year. Both are now linked to the Curia group’s website.

"The addition of LakePharma and Integrity Bio demonstrates our commitment to expanding and deepening our biologics capabilities,” said Curia chairman and CEO John Ratliff. “We have moved quickly to integrate our expanded organization so we can provide comprehensive technology and scientific solutions that enable customers to advance their biologics candidates from R&D through manufacturing.”

The rebranding is more than a name change, Curia said, noting that the the combined organization “brings a singular focus on creating a distinctive customer experience designed to accelerate projects and navigate complexity.” The US group, which offers products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers, employs 3,700 people at 29 locations in the US Europe and Asia.

Author: Dede Williams, Freelance Journalist